Bonnie Anderson - Veracyte CEO
| VCYT Stock | USD 19.90 0.07 0.35% |
CEO
Ms. Bonnie H. Anderson serves as Chairman of the Board, Chief Executive Officer of the Company. She has served as our cofounder, Chief Executive Officer and as a member of our board of directors since February 2008 and as the Chairman of our board of directors since December 2016. From August 2013 to February 2017, she also served as our President. Prior to joining us, Ms. Anderson was an independent strategic consultant from April 2006 to January 2008, including as a strategic consultant for us from July 2007 to January 2008. Ms. Anderson was a Vice President at Beckman Coulter, Inc., a manufacturer of biomedical testing instrument systems, tests and supplies, from September 2000 to March 2006. Ms. Anderson currently serves as a member of the board of directors of Castle Biosciences, Inc. and as a trustee emeritus of the Keck Graduate Institute of Applied Life Sciences since 2017.
| Age | 66 |
| Tenure | 7 years |
| Address | 6000 Shoreline Court, South San Francisco, CA, United States, 94080 |
| Phone | 650 243 6300 |
| Web | https://www.veracyte.com |
Veracyte Management Efficiency
Return On Tangible Assets is likely to drop to -0.23 in 2024. Return On Capital Employed is likely to drop to -0.01 in 2024. At this time, Veracyte's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 1.2 B in 2024, whereas Non Current Liabilities Total is likely to drop slightly above 19.6 M in 2024. Veracyte's management efficiency ratios could be used to measure how well Veracyte manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 7 records | CEO Age | ||
| Robert Blum | Cytokinetics | 60 | |
| Raymond Stevens | Structure Therapeutics American | 60 | |
| Scott Struthers | Crinetics Pharmaceuticals | 62 | |
| Arlene Morris | Syndax Pharmaceuticals | 63 | |
| James Porter | Nuvalent | 48 | |
| Mark Goldsmith | Revolution Medicines | 62 | |
| Briggs Morrison | Syndax Pharmaceuticals | 56 | |
Management Performance
| Return On Equity | -0.0702 | ||||
| Return On Asset | -0.0099 |
Veracyte Leadership Team
Elected by the shareholders, the Veracyte's board of directors comprises two types of representatives: Veracyte inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Veracyte. The board's role is to monitor Veracyte's management team and ensure that shareholders' interests are well served. Veracyte's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Veracyte's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shelly Guyer, CFO, Principal Accounting Officer and Member of Non-Management Equity Award Committee | ||
| Brian Atwood, Chairman of the Board | ||
| Neil Barth, Chief Medical Officer | ||
| Christopher Hall, COO | ||
| Mark Ho, Principal Accounting Officer | ||
| Robert Epstein, Director | ||
| Kevin Gordon, Director | ||
| Karin Eastham, Director | ||
| Evan Jones, Director | ||
| Keith Kennedy, CFO | ||
| Corinne Danan, Senior President | ||
| Tina Nova, Director | ||
| Bonnie Anderson, Co-Founder, CEO and President Director and Member of Non-Management Equity Award Committee | ||
| John Bishop, Director | ||
| Angie McCabe, IR Contact Officer | ||
| Rebecca Chambers, Executive CFO | ||
| Jonathan Wygant, VP Officer | ||
| Jackie Cossmon, IR Contact Officer | ||
| Beverly CPA, VP Controller | ||
| Julie Brooks, Executive Vice President General Counsel, Secretary | ||
| Steven French, Senior Officer | ||
| Fred Cohen, Director | ||
| Robert Brainin, Executive Officer | ||
| John Leite, Chief Business | ||
| Annie McGuire, Sr Counsel | ||
| Tracy Morris, VP Communications | ||
| Jesse Treu, Director | ||
| Phillip MD, Chief Officer | ||
| John Hanna, Chief Commercial Officer | ||
| Karen Possemato, Communications Marketing | ||
| Giulia Kennedy, Chief Scientific Officer, Chief Medical Officer | ||
| Marc Stapley, CEO Director |
Veracyte Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Veracyte a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0702 | ||||
| Return On Asset | -0.0099 | ||||
| Profit Margin | (0.21) % | ||||
| Operating Margin | 0 % | ||||
| Current Valuation | 1.29 B | ||||
| Shares Outstanding | 75.07 M | ||||
| Shares Owned By Insiders | 1.14 % | ||||
| Shares Owned By Institutions | 97.14 % | ||||
| Number Of Shares Shorted | 3.64 M | ||||
| Price To Earning | (10.61) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Veracyte is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Veracyte Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Veracyte Stock. Highlighted below are key reports to facilitate an investment decision about Veracyte Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Veracyte. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing. For more information on how to buy Veracyte Stock please use our How to Invest in Veracyte guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Complementary Tools for Veracyte Stock analysis
When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
Is Veracyte's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Veracyte. If investors know Veracyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Veracyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.02) | Revenue Per Share 4.97 | Quarterly Revenue Growth 0.223 | Return On Assets (0.01) | Return On Equity (0.07) |
The market value of Veracyte is measured differently than its book value, which is the value of Veracyte that is recorded on the company's balance sheet. Investors also form their own opinion of Veracyte's value that differs from its market value or its book value, called intrinsic value, which is Veracyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Veracyte's market value can be influenced by many factors that don't directly affect Veracyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Veracyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Veracyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Veracyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.